{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:17:16Z","timestamp":1790140636434,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011017","name":"American Academy for Cerebral Palsy and Developmental Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015713","name":"University of Michigan Office for Health Equity and Inclusion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bone.2021.116003","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T13:30:07Z","timestamp":1620653407000},"page":"116003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Osteoporosis medication is associated with mortality risk reduction among adults with epilepsy: An observational study"],"prefix":"10.1016","volume":"150","author":[{"given":"Daniel G.","family":"Whitney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2021.116003_bb0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.seizure.2010.04.013","article-title":"Fractures in epilepsy children","volume":"19","author":"Gniatkowska-Nowakowska","year":"2010","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.bone.2021.116003_bb0010","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1528-1167.2009.02082.x","article-title":"Bone mineral density in children, adolescents, and young adults with epilepsy","volume":"50","author":"Coppola","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.bone.2021.116003_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/01.wnl.0000284595.45880.93","article-title":"Progressive bone deficit in epilepsy","volume":"70","author":"Sheth","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.bone.2021.116003_bb0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/epi.16465","article-title":"The mortality burden attributable to nontrauma fracture for privately insured adults with epilepsy","volume":"61","author":"Whitney","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2021.116003_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.seizure.2016.11.013","article-title":"Physical and mental health comorbidities of epilepsy: population-based cross-sectional analysis of 1.5 million people in Scotland","volume":"45","author":"Weatherburn","year":"2017","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.bone.2021.116003_bb0030","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/epi.13817","article-title":"The prevalence of anxiety and associated factors in persons with epilepsy","volume":"58","author":"Pham","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.bone.2021.116003_bb0035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/epi.13769","article-title":"Anxiety and depressive disorders in people with epilepsy: a meta-analysis","volume":"58","author":"Scott","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2021.116003_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.annepidem.2018.11.003","article-title":"The contribution of neurologic disorders to the national prevalence of depression and anxiety problems among children and adolescents","volume":"29","author":"Whitney","year":"2019","journal-title":"Ann. Epidemiol."},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/epi.13603","article-title":"Epidemiology commission of the international league against, premature mortality of epilepsy in low- and middle-income countries: a systematic review from the mortality task force of the international league against epilepsy","volume":"58","author":"Levira","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.13604","article-title":"Epidemiology commission of the international league against, the burden of premature mortality of epilepsy in high-income countries: a systematic review from the mortality task force of the international league against epilepsy","volume":"58","author":"Thurman","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2021.116003_bb0055","doi-asserted-by":"crossref","first-page":"106411","DOI":"10.1016\/j.eplepsyres.2020.106411","article-title":"Risk for respiratory and cardiovascular disease and mortality after non-trauma fracture and the mediating effects of respiratory and cardiovascular disease on mortality risk among adults with epilepsy","volume":"166","author":"Whitney","year":"2020","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.bone.2021.116003_bb0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.seizure.2017.02.004","article-title":"Epidemiological study of mortality in epilepsy in a Spanish population","volume":"46","author":"Chamorro-Munoz","year":"2017","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.bone.2021.116003_bb0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/WNL.0000000000002390","article-title":"Cause of death and predictors of mortality in a community-based cohort of people with epilepsy","volume":"86","author":"Keezer","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.bone.2021.116003_bb0070","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.seizure.2014.07.002","article-title":"Trends in reporting injury as a cause of death among people with epilepsy in the U.S., 1981\u20132010","volume":"23","author":"Chang","year":"2014","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.bone.2021.116003_bb0075","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/epi.12351","article-title":"Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial","volume":"54","author":"Lazzari","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2021.116003_bb0080","series-title":"Epilepsia In Press","article-title":"Effectiveness of osteoporosis medication on site-specific fracture risk attenuation among adults with epilepsy","author":"Whitney","year":"2020"},{"issue":"11","key":"10.1016\/j.bone.2021.116003_bb0085","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3816","article-title":"Reduced bone loss is associated with reduced mortality risk in subjects exposed to nitrogen bisphosphonates: a mediation analysis","volume":"34","author":"Bliuc","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bone.2021.116003_bb0090","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00198-018-4806-0","article-title":"Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study","volume":"30","author":"Bliuc","year":"2019","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.bone.2021.116003_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198006","article-title":"Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study","volume":"13","author":"van Geel","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bone.2021.116003_bb0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2021.116003_bb0105","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/jor.24675","article-title":"Nontrauma fracture increases risk for respiratory disease among adults with cerebral palsy","volume":"38","author":"Whitney","year":"2020","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2021.116003_bb0110","doi-asserted-by":"crossref","first-page":"115376","DOI":"10.1016\/j.bone.2020.115376","article-title":"The cardiovascular disease burden of non-traumatic fractures for adults with and without cerebral palsy","author":"Whitney","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2021.116003_bb0115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jor.24515","article-title":"Low-trauma fracture increases 12-month incidence of cardiovascular disease for adults with cerebral palsy","volume":"38","author":"Whitney","year":"2020","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2021.116003_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.annepidem.2020.01.003","article-title":"Risk of advanced chronic kidney disease among adults with spina bifida","volume":"43","author":"Whitney","year":"2020","journal-title":"Ann. Epidemiol."},{"issue":"9","key":"10.1016\/j.bone.2021.116003_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030490","article-title":"Economic burden of paediatric-onset disabilities among young and middle-aged adults in the USA: a cohort study of privately insured beneficiaries","volume":"9","author":"Whitney","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2021.116003_bb0130","doi-asserted-by":"crossref","first-page":"115060","DOI":"10.1016\/j.bone.2019.115060","article-title":"The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities","volume":"129","author":"Whitney","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116003_bb0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jor.24515","article-title":"Low-trauma fracture increases 12-month incidence of cardiovascular disease for adults with cerebral palsy","volume":"38","author":"Whitney","year":"2019","journal-title":"J. Orthop. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dis.2005.8.1","article-title":"Developing a computer algorithm to identify epilepsy cases in managed care organizations","volume":"8","author":"Holden","year":"2005","journal-title":"Dis. Manag."},{"issue":"11","key":"10.1016\/j.bone.2021.116003_bb0145","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","article-title":"Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis","volume":"29","author":"Liu","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med. Care"},{"key":"10.1016\/j.bone.2021.116003_bb0155","series-title":"Epilepsia In Press","article-title":"The mortality burden attributable to non-trauma fracture for privately insured adults with epilepsy","author":"Whitney","year":"2020"},{"key":"10.1016\/j.bone.2021.116003_bb0160","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Stat."},{"key":"10.1016\/j.bone.2021.116003_bb0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.bone.2021.116003_bb0170","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.bone.2021.116003_bb0175","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.bone.2021.116003_bb0185","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bone.2021.116003_bb0190","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00198-007-0429-6","article-title":"Excess mortality following hip fracture: the role of underlying health status","volume":"18","author":"Tosteson","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2021.116003_bb0195","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116003_bb0200","doi-asserted-by":"crossref","first-page":"115566","DOI":"10.1016\/j.bone.2020.115566","article-title":"Bisphosphonates and lifespan","volume":"141","author":"Center","year":"2020","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2021.116003_bb0205","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1210\/jc.2015-3467","article-title":"Preadmission bisphosphonate and mortality in critically ill patients","volume":"101","author":"Lee","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2021.116003_bb0210","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00003088-200342100-00001","article-title":"Bone as an effect compartment: models for uptake and release of drugs","volume":"42","author":"Stepensky","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.bone.2021.116003_bb0215","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1248\/bpb.32.1193","article-title":"Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss","volume":"32","author":"Kwak","year":"2009","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.bone.2021.116003_bb0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bone.2008.03.030","article-title":"Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors","volume":"43","author":"Luckish","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2021.116003_bb0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neulet.2012.02.070","article-title":"A meta-analysis of pro-inflammatory cytokines in the plasma of epileptic patients with recent seizure","volume":"514","author":"Yu","year":"2012","journal-title":"Neurosci. Lett."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:17Z","timestamp":1762659737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":45,"alternative-id":["S8756328221001654"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis medication is associated with mortality risk reduction among adults with epilepsy: An observational study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116003"}}